SOMAprobes diagnostic innovations powered by nucleases
The technological opportunity represented by SOMAprobes leverages these nucleases as diagnostic markers in the design of devices for in vitro diagnostics, and especially in clinical applications such as sepsis and detection of viruses such as Coronavirus.
SOMAprobes technology has the capability to identify patients with active coronavirus infection, using a saliva sample in less then one hour
I+D + Financial award
Based on many years of research on the biology of nucleases and the use of oligonucleotides for clinical applications,
SOMAprobes co-founders, Frank Hernandez, PhD and Luiza I. Hernandez, PhD discover the utility of nuclease activity as biomarker for detection of bacterial infections and cancer. PhD discover the utility of nuclease activity as biomarker for detection of bacterial infections and cancer. These findings along with the sound expertise in business development and corporate strategy of Miguel Mulet, PhD, MBA (co-founder) lay the foundation of SOMAprobes company (San Sebastian, Spain) with the aim of developing commercial products based on this technology.
SOMAprobes was awarded for the best business idea by BIC Gipuzkoa and the Government of Basque Country, receiving a financial support of 50K €.
SOMAprobes designs and validates a tailored nucleic acid probe for bacteria detection for several in vitro and in vivo applications.
excellence from the European Commission (SME Phase 1) and a national grant of 94K € from the Horizonte PYME Programme.
Financial grant and
Innovation Agency to implement the company business plan. This allows SOMAprobes to develop and validate in-house the first prototype of its technology.
SOMAprobes investigate the possibility of integrating into the test strip, the detection of bacterial resistance to antibiotics. A patent application EP17382590.2 Lateral flow assay for detecting the presence of a specific mammalian cell or bacteria in a biological sample is submitted to EPO.
An International Patent Application (PCT/EP2018/073525-Lateral flow assay for detecting the presence of a specific mammalian cell or bacteria in a biological sample) is submitted to EPO to protect the IPR of the SOMAprobes innovation.
Financial growth and
NuSep is a diagnostic test for sepsis based on the detection of nuclease activity.
NuCor is a rapid lateral flow immunoassay test intended for detecting active infections with coronavirus, including SARS-CoV-2 that causes COVID-19. The test is performed with self-collected saliva samples.